A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

From today many with stage 3B to stage 4 melanoma will now have wider access to Keytruda and the branded drug Tafinlar and Mekinist. Melanoma New Zealand Chief executive Andrea Newland says this ...

Cancer specialists and patients have welcomed news that three potentially life-saving skin cancer medicines are to be funded.

The FDA first approved a BRAF plus MEK inhibitor combination with its green light for GSK’s dabrafenib (Tafinlar) plus trametinib (Mekinist) in 2014, however, a year after each of those agents ...

Pharmac has made decisions to: Widen access to pembrolizumab (branded as Keytruda) Fund dabrafenib (branded as Tafinlar) and trametinib (branded as Mekinist) for the first time. Dabrafenib and ...

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful ...

which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.MEKINIST® is a registered trademark owned by or licensed to Novartis AG, its subsidiaries ...

The decision includes widening access to pembrolizumab (branded as Keytruda), and funding dabrafenib, (Tafinlar) and trametinib (Mekinist), for the first time. Pharmac director pharmaceuticals ...

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful ...